ALPHA 2 RECEPTORS, LUTEAL DEPRESSION & GONADAL HORMONES

描述（改编自申请人的摘要）PI最近 发现α-2肾上腺素受体的结合增加（特别是在高血压患者中）。 亲和位点）。 这种增长是 类似于患者血小板中α-2肾上腺素受体结合的变化 严重抑郁症患者， 烦躁的症状 拟议的项目旨在确认这种可能的生物 标记物及其与性腺激素基线水平的相关性 激素，情绪和行为，以及其在症状和 月经周期的无症状阶段。 的作用 下丘脑-垂体-性腺系统将通过研究进一步阐明 绝经前和绝经后妇女的α-2受体结合 雌激素替代疗法 将在60名育龄妇女中研究α-2肾上腺素受体结合。 寻求经前焦虑综合征治疗的年龄，以及20 绝经后妇女谁将得到雌激素替代疗法，和两个 对照组：20例无经前情绪的健康女性， 行为改变，但有身体的变化，和20名妇女谁没有PMC。 PMC将保证治疗的妇女将重复以下测试 抑制排卵和性腺激素的波动与3 治疗方式产生：a）低水平的性腺激素; B） 更高水平的雌激素，以及c）三种不同水平的孕酮。 这些研究应该会导致第一个可测试的生物学建议 标记烦躁PMC，并应阐明性腺的影响， 肾上腺素受体上的激素，可能与生殖相关 烦躁症状的形成。 如果与肾脏相关，症状相关，以及 雌激素相关的α-2结合变化被发现，他们可能有 对未来治疗方法设计的影响。

DESCRIPTION (Adapted from the Applicant's Abstract) The PI has recently found increased binding of alpha-2 adrenoceptors (especially in the high affinity site) in platelets of women with dysphoric PMC. That increase was similar to changes in alpha-2 adrenoceptor binding in platelets of patients with major depressive disorder and highly correlated with severity of dysphoric symptoms. The proposed project is aimed at confirmation of that possible biological marker and elucidation of its association with baseline levels of gonadal hormones, mood, and behavior, as well as its changes during symptomatic and asymptomatic phases of the menstrual cycle. The role of the hypothalamo-pituitary-gonadal system will be further clarified by studies of alpha-2 receptor binding in postmenopausal women before and during estrogen replacement therapy. Alpha-2 adrenoceptor binding will be studied in 60 women of reproductive age who seek treatment for premenstrual dysphoric syndromes, as well as 20 post-menopausal women who will get estrogen replacement therapy, and two control groups: 20 healthy women who do not have premenstrual mood and behavioral changes but have physical changes, and 20 women who have no PMC. Women whose PMC will warrant treatment will repeat the tests following suppression of ovulation and fluctuations of gonadal hormones with 3 treatment modalities creating: a) low levels of gonadal hormones; b) higher levels of estrogen, and c) three different levels of progesterone.. The studies should result in a suggestion of the first testable biological marker for dysphoric PMC and should shed light on the influence of gonadal hormones on an adrenoceptor that might be involved in hormonally related dysphoric symptoms formation. If menstrually related, symptom related, and estrogen related alpha-2 binding changes are found, they might have implications for the design of future treatment approaches.